# Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

> **NCT04317651** · — · UNKNOWN · sponsor: **Fondazione Ricerca Traslazionale** · enrollment: 500 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Advanced Cancer
- Metastatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04317651
- **Lead sponsor:** Fondazione Ricerca Traslazionale
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-16
- **Primary completion:** 2021-12
- **Final completion:** 2022-06
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04317651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04317651, "Crizotinib in ALK Rearranged Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04317651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*